Download PDF
Thromb Haemost 1993; 70(02): 301-306
DOI: 10.1055/s-0038-1649570
Original Articles
Fibrinolysis
Schattauer GmbH Stuttgart

The Roles of α2-Antiplasmin and Plasminogen Activator Inhibitor 1 (PAI-1) in the Inhibition of Clot Lysis

Linda A Robbie
The Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland, UK
,
Nuala A Booth
1   Department of Molecular and Cell Biology, University of Aberdeen, Marischal College, Aberdeen, Scotland, UK
,
Alison M Croll
The Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland, UK
,
Bruce Bennett
The Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland, UK
› Author Affiliations
Further Information

Publication History

Received 14 September 1992

Accepted after revision 05 February 1993

Publication Date:
04 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The relative importance of the two major inhibitors of fibrinolysis, α2-antiplasmin (α2-AP) and plasminogen activator inhibitor (PAI-1), were investigated using a simple microtitre plate system to study fibrin clot lysis in vitro. Cross-linked fibrin clots contained plasminogen and tissue plasminogen activator (t-PA) at concentrations close to physiological. Purified α2-AP and PAI-1 caused dose-dependent inhibition. All the inhibition due to normal plasma, either platelet-rich or poor, was neutralised only by antibodies to α2-AP. Isolated platelets, at a final concentration similar to that in blood, 2.5 × 108/ml, markedly inhibited clot lysis. This inhibition was neutralised only by antibodies to PAI-1. At the normal circulating ratio of plasma to platelets, α2-AP was the dominant inhibitor. When the platelet:plasma ratio was raised some 20-fold, platelet PAI-1 provided a significant contribution. High local concentrations of PAI-1 do occur in thrombi in vivo, indicating a role for PAI-1, complementary to that of α2-AP, in such situations.

 

  • References

  • 1 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedGoogle Scholar
  • 2 Lijnen HR, Collen D. Interactions of plasminogen activators and inhibitors with plasminogen and fibrin. Semin Thromb Hemostas 1982; 8: 2-10
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue-plasminogen activators. Role of fibrin. J Biol Chem 1982; 257: 2912-2919
    PubMedGoogle Scholar
  • 4 Collen D. Identification of some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-216
    CrossrefPubMedGoogle Scholar
  • 5 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
    PubMedGoogle Scholar
  • 6 Moroi M, Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. J Biol Chem 1976; 251: 5956-5965
    PubMedGoogle Scholar
  • 7 Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem 1977; 78: 19-26
    CrossrefPubMedGoogle Scholar
  • 8 Plow EF, Collen D. The presence and release of α2-antiplasmin from human platelets. Blood 1981; 58: 1069-1074
    PubMedGoogle Scholar
  • 9 Kruithof EKO, Tran-Thang C, Ransijin A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
    PubMedGoogle Scholar
  • 10 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-333
    CrossrefPubMedGoogle Scholar
  • 11 Declerck PJ, Alessi MC, Verstreken EKO, Kruithof I, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzymelinked immunosorbent assay. Blood 1988; 71: 220-225
    PubMedGoogle Scholar
  • 12 Sprengers ED, Akkerman JWN, Jansen BG. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemostas 1986; 55: 325-329
    PubMedGoogle Scholar
  • 13 Simpson AJ, Booth NA, Moore NR, Bennett B. The platelet and plasma pools of plasminogen activator inhibitor PAI-1 vary independently in disease. Br J Haematol 1990; 75: 543-548
    CrossrefPubMedGoogle Scholar
  • 14 Kruithof EKO, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemostas 1988; 59: 7-12
    PubMedGoogle Scholar
  • 15 Chmielewska J, Ranby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen activator inhibitor. Biochem J 1988; 251: 327-332
    CrossrefPubMedGoogle Scholar
  • 16 Sakata Y, Aoki N. Cross-linking of α2-antiplasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-297
    CrossrefPubMedGoogle Scholar
  • 17 Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemostas 1984; 10: 24-41
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor typel (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA) Binding of t-PA-PAI-1 complexes to fibrin mediated by both finger and kringle-2 domain of t-PA. J Clin Invest 1989; 84: 647-655
    CrossrefPubMedGoogle Scholar
  • 19 Keijer J, Linders M, van Zonneveld A-J, Ehrlich HJ, de Boer J-P, Pannekoek H. The interaction of plasminogen activator inhibitor 1 (PAI-1) with plasminogen activators (t-PA, u-PA) and fibrin: localization of interaction sites and physiological relevance. Blood 1991; 78: 401-409
    PubMedGoogle Scholar
  • 20 Booth NA, Anderson JA, Bennett B. Platelet release protein which inhibits plasminogen activators. J Clin Pathol 1985; 38: 825-830
    CrossrefPubMedGoogle Scholar
  • 21 de Fouw NJ, de Jong YF, Haverkate F, Bertina RM. The influence of thrombin and platelets on fibrin clot lysis rates in vitro: a study using a clot lysis system consisting of purified human proteins. Fibrinolysis 1988; 2: 235-244
    PubMedGoogle Scholar
  • 22 Jones AJS, Meunier AM. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modelling and measurement of catalytic constants for plasminogen activation during fibrinolysis. Thromb Haemostas 1990; 64: 455-463
    PubMedGoogle Scholar
  • 23 MacGregor IR, Booth NA. An enzyme-linked immunosorbent assay (ELISA) used to study the cellular secretion of endothelial plasminogen activator inhibitor (PAI). Thromb Haemostas 1988; 59: 68-72
    PubMedGoogle Scholar
  • 24 Deutsch DG, Mertz ET. Plasminogen purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
    CrossrefPubMedGoogle Scholar
  • 25 Booth NA, MacGregor IR, Hunter NR, Bennett B. Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterization. Eur J Biochem 1987; 165: 595-600
    CrossrefPubMedGoogle Scholar
  • 26 Paramo JA, Gascoine PS, Pring JB, Gaffney PJ. The relative inhibition by α2-antiplasmin and plasminogen activator inhibitor-1 of clot lysis in vitro. Fibrinolysis 1990; 4: 169-175
    PubMedGoogle Scholar
  • 27 Lambers JWJ, Cammenga M, Konig BW, Mertens K, Pannekoek H, Van Mourik JA. Activation of human endothelial type plasminogen activator inhibitor by negatively charged phospholipids. J Biol Chem 1987; 262: 17492-17496
    PubMedGoogle Scholar
  • 28 Booth NA, Anderson JA, Bennett B. The plasma inhibitors of plasminogen activator, studied by a zymographic technique. Thromb Res 1985; 38: 261-267
    CrossrefPubMedGoogle Scholar
  • 29 Reith AR, Bennett B, Booth NA. Plasminogen activator inhibitor (PAI-2) in pregnancy plasma and ovarian cysts, studied by zymography after non-denaturing gel electrophoresis. Fibrinolysis 1989; 3: 159-163
    PubMedGoogle Scholar
  • 30 Booth NA, Croll AM, Bennett B. The activity of plasminogen activator inhibitor-1 (PAI-1) of human platelet. Fibrinolysis 1990; 4: 138-140
    PubMedGoogle Scholar
  • 31 Booth NA, Robbie LA, Croll AM, Bennett B. Lysis of platelet-rich thrombi: the role of PAI-1. NY Acad Sci USA 1992; 667: 70-86
    PubMedGoogle Scholar
  • 32 Potter van LoonBJ, Rijken DC, Brommer EJP, van der MaasAPC. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemostas 1992; 67: 101-105
    PubMedGoogle Scholar
  • 33 Levi M, Biemond BJ, van Zonnevald A-J, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-312
    CrossrefPubMedGoogle Scholar
  • 34 Reed GL, Matsueda GR, Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of α2-antiplasmin to fibrin. Thromb Haemostas 1992; 68: 315-320
    PubMedGoogle Scholar